Abstract
Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.
Keywords:
Chronic myeloid leukemia; omacetaxine mepesuccinate; tyrosine kinase inhibitor.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents, Phytogenic / chemistry
-
Antineoplastic Agents, Phytogenic / pharmacology
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Blast Crisis / drug therapy
-
Codon
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Fusion Proteins, bcr-abl / genetics
-
Harringtonines / chemistry
-
Harringtonines / pharmacology
-
Harringtonines / therapeutic use*
-
Homoharringtonine
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Leukemia, Myeloid, Accelerated Phase / drug therapy
-
Leukemia, Myeloid, Chronic-Phase / drug therapy
-
Mutation
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents, Phytogenic
-
BCR-ABL1 fusion protein, human
-
Codon
-
Harringtonines
-
Homoharringtonine
-
Fusion Proteins, bcr-abl